Kolorektales Karzinom: Screening und Surveillance bei chronisch entzündlichen Darmerkrankungen − Konsensus der Arbeitsgruppe für chronisch entzündliche Darmerkrankungen der ÖGGH

Zusammenfassung

Patienten mit Colitis ulcerosa und Morbus Crohn des Kolons haben in Abhängigkeit von Krankheitsdauer, Krankheitsausdehnung, entzündlicher Aktivität und dem evtl. Vorliegen weiterer Risikofaktoren ein erhöhtes Risiko für ein kolorektales Karzinom (KRK). Ziel ist es daher, dieses Risiko möglichst gering zu halten bzw. frühzeitig dysplastische und maligne Veränderungen zu erkennen. Die Arbeitsgruppe für chronisch entzündliche Darmerkrankungen (CED) der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) erarbeitete Konsensus-Statements zu folgenden Themen: Risiko für ein kolorektales Karzinom, Screening und Surveillance, Durchführung einer Surveillance-Koloskopie, Dysplasie und ihr Management sowie Chemoprävention. Der Konsens soll das Bewusstsein über das erhöhte Risiko für KRK bei CED stärken und das standardisierte Vorgehen in Hinblick auf präventive Maßnahmen fördern.

Abstract

Patients with ulcerative colitis and Crohn’s colitis are at increased risk of colorectal cancer (CRC). This risk is dependent on the duration and extent of disease, inflammatory activity and possible additional risk factors. Thus, the aim is to reduce this risk and to detect dysplastic and malignant lesions at an early stage. The working group for Inflammatory Bowel Diseases (IBD) of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) has developed consensus statements on the following topics: risk of colorectal cancer, screening and surveillance, procedure of surveillance colonoscopy, dysplasia and its management, and chemoprevention. This consensus is intended to increase awareness of the increased risk of CRC in IBD and to support a standardised approach in cancer prevention.

Schlüsselwörter

chronisch entzündliche Darmerkrankung - Colitis ulcerosa - Morbus Crohn - kolorektales Karzinom - Surveillance

Key words

chronic inflammatory bowel disease - ulcerative colitis - Crohn’s disease - colorectal cancer - surveillance

• Literatur

• 1 Herrinton LJ, Liu L, Levin TR et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gstroenterology 2012; 143: 382-389
• 2 Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220-228
• 3 Warren S, Sommers S. Cicatrizing enteritis as a pathological entity. Am J Pathol 1948; 24: 475-501
• 4 Munkholm P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1-5
• 5 Söderlund S, Brandt L, Lapidus A et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561-1567
• 6 Collins PD, Mpofu C, Watson AJ et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; CD000279
• 7 Biancone L, Michetti P, Travis S et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2: 63-92
• 8 Farraye FA, Odze RD, Eaden J et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-774
• 9 Cairns SR, Scholefield JH, Steele RJ et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689
• 10 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535
• 11 Rutter MD, Saunders BP, Wilkinson KH et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038
• 12 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645
• 13 Jess T, Simonsen J, Jørgensen KT et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381
• 14 Ekbom A, Helmick C, Zack M et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990; 336: 357-359
• 15 Jess T, Gamborg M, Matzen P et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729
• 16 Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 2006; 23: 1097-1104
• 17 Lutgens MW, Vleggaar FP, Schipper ME et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-1251
• 18 Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-1233
• 19 Heuschen UA, Hinz U, Allemeyer EH et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-847
• 20 Haskell H, Andrews CWJr, Reddy SI et al. Pathologic features and clinical significance of “backwash” ileitis in ulcerative colitis. Am J Surg Pathol 2005; 29: 1472-1481
• 21 Friedman S, Rubin PH, Bodian C et al. Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology 2001; 120: 820-826
• 22 Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
• 23 Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105 quiz 1340–1341
• 24 Velayos FS, Loftus EV Jr, Jess T et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology 2006; 130: 1941-1949
• 25 Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816
• 26 Soetikno RM, Lin OS, Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54
• 27 Jørgensen KK, Lindström L, Cvancarova M et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012; 45: 1021-1029
• 28 Askling J, Dickman PW, Karlén P et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001; 120: 1356-1362
• 29 Ky A, Sohn N, Weinstein MA et al. Carcinoma arising in anorectal fistulas of Crohn’s disease. Dis Colon Rectum 1998; 41: 992-996
• 30 Connell WR, Sheffield JP, Kamm MA et al. Lower gastrointestinal malignancy in Crohn’s disease. Gut 1994; 35: 347-352
• 31 Sobala A, Herbst F, Novacek G et al. Colorectal carcinoma and preceding fistula in Crohn’s disease. Journal of Crohn’s and Colitis 2010; 4: 189-193
• 32 Karlen P, Kornfeld D, Brostrom O et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-714
• 33 Lashner BA, Turner BC, Bostwick DG et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990; 35: 349-352
• 34 Choi PM, Nugent FW, Schoetz DJ et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-424
• 35 Van Assche G et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Special situations. Journal of Crohn’s and Colitis 2012; http://dx.doi.org/10.1016/j.crohns.2012.09.005
• 36 Cairns SR, Scholefield JH, Steele RJ et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689
• 37 Melville DM, Jass JR, Morson BC et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989; 20: 1008-1014
• 38 Barcley RL, Vicari JJ, Doughty AS et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 335: 2533-2541
• 39 Thomas-Gibson S, Rogers P, Cooper S et al. Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. Endoscopy 2006; 38: 456-460
• 40 Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002; 51 (Suppl. 05) V10-V12
• 41 Subramanian V, Mannath J, Ragunath K et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 304-312
• 42 Kudo S, Tamura S, Nakajima T et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996; 44: 8-14
• 43 Wu L, Li P, Wu J et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2010; 14: 416-420
• 44 Günther U, Kusch D, Heller F et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis 2011; 26: 667-672
• 45 Marion J, Waye J, Present D et al. Chromoendoscopy-Targeted Biopsies Are Superiorto Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial. Am J Gastroenterol 2008; 103: 2342-2349
• 46 Rubin CE, Haggitt RC, Brumer GC et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gstroenterology 1992; 103: 1611-1620
• 47 Ignjatovic A, East J, Subramanian V et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012; 107: 885-890
• 48 Pellisé M, López-Cerón M, Rodríguez de Miguel C et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc 2011; 74: 840-848
• 49 Dekker E, van den Broek F, Reitsma J et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007; 39: 216-221
• 50 Matsumoto T, Nakamura S, Moriyama T et al. Autofluorescence imaging colonoscopy for the detection of dysplastic lesions in ulcerative colitis: a pilot study. Colorectal Dis 2010; 12 (10) e291-e297
• 51 Odze RD, Goldblum J, Noffsinger A et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002; 15: 379-386
• 52 Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994; 343: 71-74
• 53 Connell WR, Lennard-Jones JE, William CB et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944
• 54 Kariv R, Remzi FH, Lian L et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology 2010; 139: 806-812
• 55 Ullman TA, Croog T, Harpaz N et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-1319
• 56 Thomas T, Abrams KA, Robinson RJ et al. Cancer risk of low-grade dysplasia in chronic ulcerative colitis: a systematic review and meta-analysis. Alimentary Pharmacology and Therapeutic 2007; 25: 657-668
• 57 Itzkowitz SH, Present DH. Consensus Conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 314-321
• 58 Friedman S, Odze RD, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 260-266
• 59 Odze RD, Farraye FA, Hecht JL et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin GastroenterolnHepatol 2004; 2: 534-541
• 60 Rubin PH, Friedman S, Harpaz N et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1295-1300
• 61 Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117: 1288-1294
• 62 Kisiel JB, Loftus EV, Harmsen WS et al. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis 2012; 18: 226-235
• 63 Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut 2006; 55: 1151-1155
• 64 Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010; 31: 202-209
• 65 Campregher C, Gasche C. Aminosalicylates. Best Pract Res Clin Gastroenterol 2011; 25: 535-546
• 66 Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353
• 67 Moody GA, Jayanthi V, Probert CS et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-1183
• 68 Eaden J, Abrams K, Ekbom A et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153
• 69 van Staa TP, Card T, Logan RF et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-1578
• 70 Rubin DT, LoSavio A, Yadron N et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 1346-1350
• 71 Jess T, Loftus EV Jr, Velayos FS et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836
• 72 Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106: 731-736
• 73 Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105
• 74 Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease:a meta-analysis of non-referral populations. Am J Gastroenterol 2012; 107: 1298-1304
• 75 Van Schaik FDM, van Oijen MGH, Smeets HM et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61: 235-240
• 76 Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695
• 77 Pardi DS, Loftus EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
• 78 Sjoqvist U, Tribukait B, Ost A et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004; 24: 3121-3127
• 79 Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95
• 80 Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 22: 783-788
• 81 Eaton JE, Silveira MG, Pardi DS et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-1645
• 82 Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678
• 83 European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267
• 84 Baars JE, Looman CW, Steyerberg EW et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011; 106: 319-328
• 85 Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192
• 86 Lashner BA, Provencher KS, Seidner DL et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32